Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors. Huo KG, Notsuda H, Fang Z, Liu NF, et al. J Thorac Oncol 2021 Oct 11. pii: S1556-0864(21)03205.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Huo KG, Notsuda H, Fang Z, Liu NF, et al. Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors. J Thorac Oncol 2021 Oct 11. pii: S1556-0864(21)03205.
PMID: 34648945